Skip to main content

Advertisement

Table 1 Baseline characteristics

From: Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program

  Rivaroxaban 10 mg bid/ 15 mg od N = 23 Rivaroxaban 15 mg bid/ 15 mg od N = 55 UFH/warfarin N = 19
Sex, male, n (%) 16 (69.6) 25 (45.5) 10 (52.6)
Age, years, mean (SD) 65.0 (9.9) 68.8 (12.2) 63.4 (18.3)
Body weight <70 kg, n (%) 15 (65.2) 41 (74.5) 15 (78.9)
Creatinine clearance <80 ml/min, n (%) 9 (39.1) 36 (65.5) 11 (57.9)
DVT only, n (%) 23 (100.0) 25 (45.5) 12 (63.2)
Unprovoked VTE, n (%) 11 (47.8) 31 (56.4) 8 (42.1)
Provoked VTE, n (%) 12 (52.2) 24 (43.6) 11 (57.9)
Previous VTE, n (%) 0 8 (14.5) 1 (5.3)
Recent surgery or trauma, n (%) 6 (26.1) 11 (20.0) 2 (10.5)
Active cancer, n (%) 2 (8.7) 3 (5.5) 2 (10.5)
Thrombophilia, n (%) 2 (8.7) 1 (1.8) 3 (15.8)
Protein S deficiency 0 0 1 (5.3 %)
Protein C deficiency 1 (4.3) 1 (1.8) 2 (10.5)
Antithrombin deficiency 1 (4.3) 0 0
Prolonged immobilization, n (%) 3 (13.0) 8 (14.5) 4 (21.1)
Intended treatment duration
3 months, n (%) 4 (17.4) 10 (18.2) 4 (21.1)
6 months, n (%) 12 (52.2) 26 (47.3) 9 (47.4)
12 months, n (%) 7 (30.4) 19 (34.5) 6 (31.6)
Mean treatment duration, days (SD) 191.8 (106.9) 196.6 (121.7) 199.8 (101.9)
Adherence to study treatment
Missing n (%) 1 (4.3) 0 0
≥50% to <80% 0 0 4 (21.1)
≥80% 22 (95.7) 55 (100.0) 15 (78.9)
  1. bid, twice daily; DVT, deep vein thrombosis; od, once daily; SD, standard deviation; UFH, unfractionated heparin; VTE, venous thromboembolism.